Updated Hyperlipidemia Guidelines Broaden Eligibility for Cholesterol Treatment

New hyperlipidemia guidelines from the American Heart Association and American College of Cardiology, published in JAMA Internal Medicine, significantly expand the proportion of adults eligible for lipid-lowering therapy. The updated guidance, which replaces the previous PCE risk assessment with PREVENT-ASCVD equations, increases eligibility for adults aged 20-79 without established cardiovascular disease from 41.3% to 54.6%. This change also lowers the risk threshold for considering treatment and elevates chronic kidney disease and HIV to standalone qualifying conditions, potentially impacting millions.